<DOC>
	<DOC>NCT01940952</DOC>
	<brief_summary>The purpose of this study is to determine whether Zydena (Udenafil) has positive effect on cognitive function in patients with Alzheimer's disease. This study is a randomized, double blind, placebo-controlled multicenter study.</brief_summary>
	<brief_title>Zydena on Cognitive Function of Alzheimer's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Signed written informed consent; Male or female subjects 50 to 90 years of age; Diagnosis of probable Alzheimer's disease according to National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria; A MiniMental State Examination (MMSE) score of ≥10 and ≤26; Global Clinical Dementia Rating ≥ 0.5; Mild to moderate (not severe) white matter hyperintensities on brain MRI performed within three years from screening; Good enough hearing and visual function to complete neuropsychological tests Caregivers living with patients or spending 10 or more hours a week with patients; Stable dose of donepezil (5mg to 10mg) for at least 60 days; If patients have been on memantine, it should be washed out for at least 60 days; Medications including anxiolytics, antipsychotics, and hypnotics may be taken if the dose has been stable for at least two weeks History of stroke within 6 months; Previous diagnosis of severe (more than 80%) intracranial artery stenosis; History of heart failure, ischemic heart disease (myocardial infarction, unstable angina, and stable angina), hypertrophic cardiomyopathy, and lifethreatening arrhythmia; Previous history of coronary artery bypass graft surgery; Severe symptom of orthostatic hypotension (orthostatic syncope or presyncope), especially when patients take alphaadrenergic blocker (Alfuzosin, Doxazosin, Naftopidil, Tamsulosin, Terazosin, Arotinolol, Carvedilol, Labetalol, Trazodone, typical and atypical antipsychotics); Uncontrolled diabetes mellitus; Proliferative diabetic retinopathy; Severe hypotension (blood pressure less than 90/50mmHg) or severe hypertension (blood pressure more than 170/100mmHg); Hepatic dysfunction (AST or ALT more than three times of upper normal limit) or renal dysfunction (serum creatinine more than 2.5mg/dL); Retinitis pigmentosa; Previous history of active peptic ulceration within one year before screening; Hematodyscrasia susceptible to priapism including sickle cell anemia, multiple myeloma, leukemia, and various bleeding disorders; History of drug abuse; Medication including nitrates/nitric oxide donor (ex: nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrate/nitrite, and Sodium nitroprusside), androgen (ex: testosterone), antiandrogen, and anticoagulants; Current cancer chemotherapy; Usage of PDE5i (Zydena, Viagra®, Levitra®, or Cialis®) within two weeks before study start; History of hypersensitive reaction to PDE5i (Zydena, Viagra®, Levitra®, or Cialis®)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>